169 related articles for article (PubMed ID: 24692425)
1. Telomerase activity analyzed with TRAP in situ provides additional information in effusions remaining equivocal after immunocytochemistry and hyaluronan analysis.
Adell E; Dejmek A
Diagn Cytopathol; 2014 Dec; 42(12):1051-7. PubMed ID: 24692425
[TBL] [Abstract][Full Text] [Related]
2. Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay.
Hansson M; Zendehrokh N; Ohyashiki J; Ohyashiki K; Westman UB; Roos G; Dejmek A
Arch Pathol Lab Med; 2008 Dec; 132(12):1896-902. PubMed ID: 19061286
[TBL] [Abstract][Full Text] [Related]
3. Telomere repeat amplification protocol (TRAP) in situ reveals telomerase activity in three cell types in effusions: malignant cells, proliferative mesothelial cells, and lymphocytes.
Zendehrokh N; Dejmek A
Mod Pathol; 2005 Feb; 18(2):189-96. PubMed ID: 15389260
[TBL] [Abstract][Full Text] [Related]
4. Pitfalls in TRAP assay in routine detection of malignancy in effusions.
Braunschweig R; Guilleret I; Delacrétaz F; Bosman FT; Mihaescu A; Benhattar J
Diagn Cytopathol; 2001 Oct; 25(4):225-30. PubMed ID: 11599105
[TBL] [Abstract][Full Text] [Related]
5. Limitations of detection of malignancy in pleural effusions using ELISA-based TRAP assay: comparison with cytological examination.
Lee WY
Cytopathology; 2005 Oct; 16(5):227-32. PubMed ID: 16181308
[TBL] [Abstract][Full Text] [Related]
6. The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey.
Paintal A; Raparia K; Zakowski MF; Nayar R
Cancer Cytopathol; 2013 Dec; 121(12):703-7. PubMed ID: 24039177
[TBL] [Abstract][Full Text] [Related]
7. Comparison of NCL-hTERT antibody reactivity and telomere repeat amplification protocol in situ in effusions.
Zendehrokh N; Rehnberg J; Dejmek A
Acta Cytol; 2007; 51(6):886-92. PubMed ID: 18077981
[TBL] [Abstract][Full Text] [Related]
8. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
[TBL] [Abstract][Full Text] [Related]
9. Static DNA cytometry as a diagnostic aid in effusion cytology: II. DNA aneuploidy for identification of neoplastic cells in equivocal effusions.
Motherby H; Nadjari B; Remmerbach T; Marcy T; Pomjanskaja N; Müller W; Knops K; Häussinger D; Strauer BE; Böcking A
Anal Quant Cytol Histol; 1998 Jun; 20(3):162-8. PubMed ID: 9642442
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic yield of pleural fluid cytology in malignant effusions: an Australian tertiary centre experience.
Loveland P; Christie M; Hammerschlag G; Irving L; Steinfort D
Intern Med J; 2018 Nov; 48(11):1318-1324. PubMed ID: 29869427
[TBL] [Abstract][Full Text] [Related]
11. Early diagnosis of mesothelioma in serous effusions using AgNOR analysis.
Pomjanski N; Motherby H; Buckstegge B; Knops K; Rohn BL; Böcking A
Anal Quant Cytol Histol; 2001 Apr; 23(2):151-60. PubMed ID: 11332082
[TBL] [Abstract][Full Text] [Related]
12. Reliably making the primary diagnosis of mesothelioma utilizing serous fluid cytology specimens: an institutional experience.
Jones TE; Geisler DL; Baskota SU; Ohori NP; Cuda J; Khader SN
J Am Soc Cytopathol; 2024; 13(3):174-182. PubMed ID: 38514361
[TBL] [Abstract][Full Text] [Related]
13. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
[TBL] [Abstract][Full Text] [Related]
14. In situ telomerase activity in pleural effusions: a promising marker for malignancy.
Dejmek A; Yahata N; Ohyashiki K; Ebihara Y; Kakihana M; Hirano T; Kawate N; Kato H
Diagn Cytopathol; 2001 Jan; 24(1):11-5. PubMed ID: 11135462
[TBL] [Abstract][Full Text] [Related]
15. Detection of malignant effusions: comparison of a telomerase assay and cytologic examination.
Braunschweig R; Yan P; Guilleret I; Delacretaz F; Bosman FT; Mihaescu A; Benhattar J
Diagn Cytopathol; 2001 Mar; 24(3):174-80. PubMed ID: 11241900
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
17. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
18. Effects of the Storage Solution Type and Prolonged Storage on the Immunoreactivity of Cells.
Ikeda K; Sato S; Chigira H; Shibuki Y; Hiraoka N
Acta Cytol; 2020; 64(4):352-359. PubMed ID: 31597129
[TBL] [Abstract][Full Text] [Related]
19. Role of Ancillary Techniques in Fluid Cytology.
Yu GH; Glaser LJ; Gustafson KS
Acta Cytol; 2020; 64(1-2):52-62. PubMed ID: 31018204
[TBL] [Abstract][Full Text] [Related]
20. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
